Alnylam Pharms Inc Drug Patent Portfolio
Alnylam Pharms Inc owns 4 orange book drugs protected by 57 US patents Given below is the list of Alnylam Pharms Inc's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11261447 | Methods for inhibition of HAO1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression | 20 Nov, 2038 | Active |
| US10208307 | Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases | 28 Jul, 2036 | Active |
| US10683501 | Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases | 28 Jul, 2036 | Active |
| US11286486 | Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases | 28 Jul, 2036 | Active |
| US12049628 | Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases | 28 Jul, 2036 | Active |
| US10478500 | Compositions and methods for inhibition of HAO1 (Hydroxyacid Oxidase 1 (Glycolate Oxidase)) gene expression | 09 Oct, 2035 | Active |
| US11446380 | Compositions and methods for inhibition of HAO1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression | 09 Oct, 2035 | Active |
| US11079379 | Methods of treating transthyretin (TTR) mediated amyloidosis | 27 Aug, 2035 | Active |
| US10612024 | Modified double-stranded RNA agents | 14 Aug, 2035 | Active |
| US11401517 | Modified double-stranded RNA agents | 14 Aug, 2035 | Active |
| US10612027 | Modified double-stranded RNA agents | 14 Aug, 2035 | Active |
| US10435692 | Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA | 26 Dec, 2034 | Active |
| US10465195 | Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA | 26 Dec, 2034 | Active |
| US10487330 | Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA | 26 Dec, 2034 | Active |
| US11060093 | Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA | 26 Dec, 2034 | Active |
| US9828606 | Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA | 26 Dec, 2034 | Active |
| US10119143 | Compositions and methods for inhibiting expression of the ALAS1 gene | 03 Oct, 2034 | Active |
| US11028392 | Compositions and methods for inhibiting expression of the ALAS1 gene | 03 Oct, 2034 | Active |
| US9133461 | Compositions and methods for inhibiting expression of the ALAS1 gene | 30 Nov, 2033 | Active |
| US10125364 | Compositions and methods for inhibiting expression of the ALAS1 gene | 15 Mar, 2033 | Active |
| US9631193 | Compositions and methods for inhibiting expression of the ALAS1 gene | 15 Mar, 2033 | Active |
| US10570391 | RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseases | 16 Nov, 2032 | Active |
| US9399775 | RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseases | 16 Nov, 2032 | Active |
| US8158601 | Lipid formulation | 10 Nov, 2030 | Active |
| US8802644 | Lipid formulation | 21 Oct, 2030 | Active |
| US8106022 | Carbohydrate conjugates as delivery agents for oligonucleotides | 12 Dec, 2029 | Active |
| US10240152 | Compositions and methods for inhibiting expression of transthyretin | 20 Oct, 2029 | Active |
| US8168775 | Compositions and methods for inhibiting expression of transthyretin | 20 Oct, 2029 | Active |
| US8741866 | Compositions and methods for inhibiting expression of transthyretin | 20 Oct, 2029 | Active |
| US9234196 | Compositions and methods for inhibiting expression of transthyretin | 20 Oct, 2029 | Active |
| US11141378 | Lipid formulations for nucleic acid delivery | 15 Apr, 2029 | Active |
| US8058069 | Lipid formulations for nucleic acid delivery | 15 Apr, 2029 | Active |
| US8492359 | Lipid formulations for nucleic acid delivery | 15 Apr, 2029 | Active |
| US8822668 | Lipid formulations for nucleic acid delivery | 15 Apr, 2029 | Active |
| US9364435 | Lipid formulations for nucleic acid delivery | 15 Apr, 2029 | Active |
| US10806791 | Carbohydrate conjugates as delivery agents for oligonucleotides | 04 Dec, 2028 | Active |
| US8828956 | Carbohydrate conjugates as delivery agents for oligonucleotides | 04 Dec, 2028 | Active |
| US9370581 | Carbohydrate conjugates as delivery agents for oligonucleotides | 04 Dec, 2028 | Active |
| US10131907 | Glycoconjugates of RNA interference agents | 24 Aug, 2028 | Active |
| US8642076 | Lipid containing formulations | 03 Oct, 2027 | Active |
| US9150605 | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation | 28 Aug, 2025 | Active |
| US8334373 | Nuclease resistant double-stranded ribonucleic acid | 27 May, 2025 | Active |
| US11530408 | Therapeutic compositions | 18 May, 2024 | Expired |
| US10273477 | Therapeutic compositions | 08 Mar, 2024 | Expired |
| US9708615 | Therapeutic compositions | 08 Mar, 2024 | Expired |
| US9708610 | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation | 01 Jan, 2024 | Expired |
| US9943538 | 2′-methoxy substituted oligomeric compounds and compositions for use in gene modulations | 04 Nov, 2023 | Expired |
| US9943539 | 2′-methoxy substituted oligomeric compounds and compositions for use in gene modulations | 04 Nov, 2023 | Expired |
| US8546143 | Compositions and methods for inhibiting expression of a target gene | 09 Jan, 2022 | Expired |
| US8362231 | RNA interference mediating small RNA molecules | 30 Mar, 2021 | Expired |
| US8372968 | RNA interference mediating small RNA molecules | 30 Mar, 2021 | Expired |
| US8552171 | RNA sequence-specific mediators of RNA interference | 30 Mar, 2021 | Expired |
| US8778902 | RNA interference mediating small RNA molecules | 30 Mar, 2021 | Expired |
| US8895718 | RNA interference mediating small RNA molecules | 30 Mar, 2021 | Expired |
| US8895721 | RNA interference mediating small RNA molecules | 30 Mar, 2021 | Expired |
| US9193753 | RNA sequence-specific mediators of RNA interference | 30 Mar, 2021 | Expired |
| US9567582 | RNA interference mediating small RNA molecules | 30 Mar, 2021 | Expired |
Latest Legal Activities on Alnylam Pharms Inc's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Alnylam Pharms Inc.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Notice of Final Determination -Election Required | 26 Jun, 2024 | US9234196 |
| Notice of Final Determination -Election Required | 26 Jun, 2024 | US8168775 |
| Notice of Final Determination -Election Required | 26 Jun, 2024 | US8741866 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 11 Jun, 2024 | US10806791 |
| Surcharge for Late Payment, Large Entity | 11 Jun, 2024 | US10806791 |
|
Maintenance Fee Reminder Mailed
Critical
| 10 Jun, 2024 | US10806791 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 28 May, 2024 | US8334373 |
| transaction for FDA Determination of Regulatory Review Period | 14 Mar, 2024 | US8828956 |
| transaction for FDA Determination of Regulatory Review Period | 14 Mar, 2024 | US8828956 |
| transaction for FDA Determination of Regulatory Review Period | 14 Mar, 2024 | US8828956 |
| transaction for FDA Determination of Regulatory Review Period | 29 Feb, 2024 | US8828956 |
| transaction for FDA Determination of Regulatory Review Period | 29 Feb, 2024 | US8828956 |
| transaction for FDA Determination of Regulatory Review Period | 29 Feb, 2024 | US8828956 |
|
FDA Final Eligibility Letter
Critical
| 30 Jan, 2024 | US8741866 |
|
FDA Final Eligibility Letter
Critical
| 30 Jan, 2024 | US9234196 |
Alnylam Pharms Inc's Drug Patent Litigations
Alnylam Pharms Inc's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Nov 22, 2010, against patent number US9150605. The petitioner , challenged the validity of this patent, with Charles Allerson et al as the respondent. Click below to track the latest information on how companies are challenging Alnylam Pharms Inc's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US8058069 | January, 2019 |
Final Written Decision
(23 Jul, 2020)
| Arbutus Biopharma Corporation | Moderna Therapeutics, Inc. |
| US9364435 | March, 2018 |
FWD Entered
(11 Sep, 2019)
| Arbutus Biopharma Corporation | Moderna Therapeutics, Inc. |
| US9150605 | November, 2010 |
Decision
(27 Feb, 2013)
| Charles Allerson et al | |
Alnylam Pharms Inc Drug Patents' Oppositions Filed in EPO
Alnylam Pharms Inc drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on May 20, 2003, by Sirna Therapeutics, Inc.. This opposition was filed on patent number EP00910510A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
| | |||
| EP17209680A | Jan, 2023 | AWA Sweden AB | Granted and Under Opposition |
| EP09731866A | Apr, 2018 | Moderna Therapeutics, Inc. | Granted and Under Opposition |
| EP09731866A | Apr, 2018 | Merck Sharp & Dohme Corporation | Granted and Under Opposition |
| EP06025389A | Dec, 2017 | Silence Therapeutics GmbH | Revoked |
| EP10011217A | Apr, 2017 | Silence Therapeutics GmbH | Opposition rejected |
| EP02702247A | Dec, 2010 | Sirna Therapeutics | Revoked |
| EP02702247A | Dec, 2010 | Silence Therapeutics AG | Revoked |
| EP05002454A | Sep, 2009 | ROQUES, Sarah Elizabeth | Granted and Under Opposition |
| EP05002454A | Sep, 2009 | Silence Therapeutics AG | Granted and Under Opposition |
| EP05002454A | Sep, 2009 | PFIZER LIMITED | Granted and Under Opposition |
| EP05002454A | Sep, 2009 | Sanofi-Aventis Deutschland GmbH | Granted and Under Opposition |
| EP05002454A | Sep, 2009 | Sirna Therapeutics | Granted and Under Opposition |
| EP02710786A | Feb, 2007 | Sirna Therapeutics | Opposition rejected |
| EP02003683A | Mar, 2006 | atugen AG | Patent maintained as amended |
| EP02003683A | Mar, 2006 | Abbott Laboratories | Patent maintained as amended |
| EP02003683A | Mar, 2006 | Sirna Therapeutics, Inc. | Patent maintained as amended |
| EP02003683A | Mar, 2006 | Quark Biotech, Inc. | Patent maintained as amended |
| EP00910510A | May, 2003 | Aventis Pharma Deutschland GmbH | Revoked |
| EP00910510A | May, 2003 | JANSSEN PHARMACEUTICA N.V. | Revoked |
| EP00910510A | May, 2003 | AstraZeneca AB | Revoked |
| EP00910510A | May, 2003 | Novartis AG | Revoked |
| EP00910510A | May, 2003 | Isis Pharmaceuticals, Inc. | Revoked |
| EP00910510A | May, 2003 | atugen AG | Revoked |
| EP00910510A | May, 2003 | Grund, Martin, Dr. | Revoked |
| EP00910510A | May, 2003 | Sirna Therapeutics, Inc. | Revoked |
Alnylam Pharms Inc's Family Patents
Alnylam Pharms Inc drugs have patent protection in a total of 53 countries. It's US patent count contributes only to 34.5% of its total global patent coverage. 3 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Alnylam Pharms Inc Drug List
Given below is the complete list of Alnylam Pharms Inc's drugs and the patents protecting them.
1. Amvuttra
Amvuttra is protected by 13 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10208307 | Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases |
28 Jul, 2036
(11 years from now)
| Active |
| US10683501 | Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases |
28 Jul, 2036
(11 years from now)
| Active |
| US11286486 | Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases |
28 Jul, 2036
(11 years from now)
| Active |
| US12049628 | Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases |
28 Jul, 2036
(11 years from now)
| Active |
| US10612024 | Modified double-stranded RNA agents |
14 Aug, 2035
(10 years from now)
| Active |
| US11401517 | Modified double-stranded RNA agents |
14 Aug, 2035
(10 years from now)
| Active |
| US10570391 | RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseases |
16 Nov, 2032
(8 years from now)
| Active |
| US9399775 | RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseases |
16 Nov, 2032
(8 years from now)
| Active |
| US8106022 | Carbohydrate conjugates as delivery agents for oligonucleotides |
12 Dec, 2029
(5 years from now)
| Active |
| US10806791 | Carbohydrate conjugates as delivery agents for oligonucleotides |
04 Dec, 2028
(4 years from now)
| Active |
| US8828956 | Carbohydrate conjugates as delivery agents for oligonucleotides |
04 Dec, 2028
(4 years from now)
| Active |
| US9370581 | Carbohydrate conjugates as delivery agents for oligonucleotides |
04 Dec, 2028
(4 years from now)
| Active |
| US10131907 | Glycoconjugates of RNA interference agents |
24 Aug, 2028
(3 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Amvuttra's drug page
2. Givlaari
Givlaari is protected by 14 patents, out of which 5 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10119143 | Compositions and methods for inhibiting expression of the ALAS1 gene |
03 Oct, 2034
(9 years from now)
| Active |
| US11028392 | Compositions and methods for inhibiting expression of the ALAS1 gene |
03 Oct, 2034
(9 years from now)
| Active |
| US9133461 | Compositions and methods for inhibiting expression of the ALAS1 gene |
30 Nov, 2033
(9 years from now)
| Active |
| US10125364 | Compositions and methods for inhibiting expression of the ALAS1 gene |
15 Mar, 2033
(8 years from now)
| Active |
| US9631193 | Compositions and methods for inhibiting expression of the ALAS1 gene |
15 Mar, 2033
(8 years from now)
| Active |
| US8106022 | Carbohydrate conjugates as delivery agents for oligonucleotides |
12 Dec, 2029
(5 years from now)
| Active |
| US8828956 | Carbohydrate conjugates as delivery agents for oligonucleotides |
04 Dec, 2028
(4 years from now)
| Active |
| US10131907 | Glycoconjugates of RNA interference agents |
24 Aug, 2028
(3 years from now)
| Active |
| US9150605 | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation |
28 Aug, 2025
(9 months from now)
| Active |
| US11530408 | Therapeutic compositions |
18 May, 2024
(5 months ago)
| Expired |
| US10273477 | Therapeutic compositions |
08 Mar, 2024
(8 months ago)
| Expired |
| US9708615 | Therapeutic compositions |
08 Mar, 2024
(8 months ago)
| Expired |
| US9708610 | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation |
01 Jan, 2024
(10 months ago)
| Expired |
| US8546143 | Compositions and methods for inhibiting expression of a target gene |
09 Jan, 2022
(2 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Givlaari's drug page
3. Onpattro
Onpattro is protected by 24 patents, out of which 10 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11079379 | Methods of treating transthyretin (TTR) mediated amyloidosis |
27 Aug, 2035
(10 years from now)
| Active |
| US8158601 | Lipid formulation |
10 Nov, 2030
(5 years from now)
| Active |
| US8802644 | Lipid formulation |
21 Oct, 2030
(5 years from now)
| Active |
| US10240152 | Compositions and methods for inhibiting expression of transthyretin |
20 Oct, 2029
(4 years from now)
| Active |
| US8168775 | Compositions and methods for inhibiting expression of transthyretin |
20 Oct, 2029
(4 years from now)
| Active |
| US8741866 | Compositions and methods for inhibiting expression of transthyretin |
20 Oct, 2029
(4 years from now)
| Active |
| US9234196 | Compositions and methods for inhibiting expression of transthyretin |
20 Oct, 2029
(4 years from now)
| Active |
| US11141378 | Lipid formulations for nucleic acid delivery |
15 Apr, 2029
(4 years from now)
| Active |
| US8058069 | Lipid formulations for nucleic acid delivery |
15 Apr, 2029
(4 years from now)
| Active |
| US8492359 | Lipid formulations for nucleic acid delivery |
15 Apr, 2029
(4 years from now)
| Active |
| US8822668 | Lipid formulations for nucleic acid delivery |
15 Apr, 2029
(4 years from now)
| Active |
| US9364435 | Lipid formulations for nucleic acid delivery |
15 Apr, 2029
(4 years from now)
| Active |
| US8642076 | Lipid containing formulations |
03 Oct, 2027
(2 years from now)
| Active |
| US8334373 | Nuclease resistant double-stranded ribonucleic acid |
27 May, 2025
(6 months from now)
| Active |
| US9943538 | 2′-methoxy substituted oligomeric compounds and compositions for use in gene modulations |
04 Nov, 2023
(1 year, 12 days ago)
| Expired |
| US9943539 | 2′-methoxy substituted oligomeric compounds and compositions for use in gene modulations |
04 Nov, 2023
(1 year, 12 days ago)
| Expired |
| US8362231 | RNA interference mediating small RNA molecules |
30 Mar, 2021
(3 years ago)
| Expired |
| US8372968 | RNA interference mediating small RNA molecules |
30 Mar, 2021
(3 years ago)
| Expired |
| US8552171 | RNA sequence-specific mediators of RNA interference |
30 Mar, 2021
(3 years ago)
| Expired |
| US8778902 | RNA interference mediating small RNA molecules |
30 Mar, 2021
(3 years ago)
| Expired |
| US8895718 | RNA interference mediating small RNA molecules |
30 Mar, 2021
(3 years ago)
| Expired |
| US8895721 | RNA interference mediating small RNA molecules |
30 Mar, 2021
(3 years ago)
| Expired |
| US9193753 | RNA sequence-specific mediators of RNA interference |
30 Mar, 2021
(3 years ago)
| Expired |
| US9567582 | RNA interference mediating small RNA molecules |
30 Mar, 2021
(3 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Onpattro's drug page
4. Oxlumo
Oxlumo is protected by 14 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11261447 | Methods for inhibition of HAO1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression |
20 Nov, 2038
(14 years from now)
| Active |
| US10478500 | Compositions and methods for inhibition of HAO1 (Hydroxyacid Oxidase 1 (Glycolate Oxidase)) gene expression |
09 Oct, 2035
(10 years from now)
| Active |
| US11446380 | Compositions and methods for inhibition of HAO1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression |
09 Oct, 2035
(10 years from now)
| Active |
| US10612024 | Modified double-stranded RNA agents |
14 Aug, 2035
(10 years from now)
| Active |
| US10612027 | Modified double-stranded RNA agents |
14 Aug, 2035
(10 years from now)
| Active |
| US11401517 | Modified double-stranded RNA agents |
14 Aug, 2035
(10 years from now)
| Active |
| US10435692 | Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA |
26 Dec, 2034
(10 years from now)
| Active |
| US10465195 | Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA |
26 Dec, 2034
(10 years from now)
| Active |
| US10487330 | Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA |
26 Dec, 2034
(10 years from now)
| Active |
| US11060093 | Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA |
26 Dec, 2034
(10 years from now)
| Active |
| US9828606 | Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA |
26 Dec, 2034
(10 years from now)
| Active |
| US8106022 | Carbohydrate conjugates as delivery agents for oligonucleotides |
12 Dec, 2029
(5 years from now)
| Active |
| US8828956 | Carbohydrate conjugates as delivery agents for oligonucleotides |
04 Dec, 2028
(4 years from now)
| Active |
| US10131907 | Glycoconjugates of RNA interference agents |
24 Aug, 2028
(3 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Oxlumo's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List